BioCentury | Feb 8, 1999
Company News

Rapigene Inc. management update

...Japan; and Karen Hedine as VP of business development, formerly VP of business development at Phytogen...
BioCentury | Apr 13, 1998
Company News

Mycogen, J.G. Boswell Co. deal

...The companies' Phytogen Seed Company LLC cotton seed joint venture acquired an Argentinian cotton seed breeding...
BioCentury | Jan 12, 1998
Company News

Mycogen, J.G. Boswell Co. deal

...The companies formed Phytogen Seed Company LLC, a joint venture that will market and develop new...
...in return for a 51 percent interest in Phytogen Seed. Boswell will contribute its existing Phytogen...
BioCentury | Sep 2, 1997
Company News

Drug Royalty Corp., Phytogen deal

...DRI invested C$3 million (US$2.16 million) in Phytogen, bringing DRI's total investment in the company to...
...bringing DRI's total investment in the company to C$4.5 million. DRI receives increased royalties on Phytogen's...
...the time of an IPO. The deal is part of a C$7 million investment in Phytogen...
BioCentury | Jun 9, 1997
Clinical News

LXR regulatory update

LXR received four U.S. patents and a notice of allowance for a U.S. patent covering its apoptotic compounds. Patent No. 5,567,425 covers methods of preventing apoptosis in cells using plant-derived inhibitors. Patent No. 5,620,888 covers...
BioCentury | Jan 13, 1997
Company News

Draxis, Mylan Laboratories deal

...on a predetermined formula. Mylan manufactures the product using bulk fine chemical paclitaxel produced by Phytogen Life Sciences Inc....
BioCentury | Jul 29, 1996
Company News

Phytogen, Mylan Laboratories Inc. deal

...Phytogen’s Phytogen International LLC subsidiary granted Mylan’s Mylan Pharmaceutical division an exclusive license to sell generic...
...division an exclusive license to sell generic taxol (paclitaxel) in the U.S., Canada and Mexico. Phytogen...
...million (US$1.1 million) to Phytogen in exchange for an undisclosed percentage of revenues from paclitaxel. Phytogen Life Sciences Inc....
BioCentury | Aug 7, 1995
Company News

Drug Royalty Corp., TPL Phytogen Inc., Peptide, Dura deal

...DRI funds are used to finance a sales force expansion. Drug Royalty Corp. (TSE:DRI) TPL Phytogen...
Items per page:
1 - 8 of 8
BioCentury | Feb 8, 1999
Company News

Rapigene Inc. management update

...Japan; and Karen Hedine as VP of business development, formerly VP of business development at Phytogen...
BioCentury | Apr 13, 1998
Company News

Mycogen, J.G. Boswell Co. deal

...The companies' Phytogen Seed Company LLC cotton seed joint venture acquired an Argentinian cotton seed breeding...
BioCentury | Jan 12, 1998
Company News

Mycogen, J.G. Boswell Co. deal

...The companies formed Phytogen Seed Company LLC, a joint venture that will market and develop new...
...in return for a 51 percent interest in Phytogen Seed. Boswell will contribute its existing Phytogen...
BioCentury | Sep 2, 1997
Company News

Drug Royalty Corp., Phytogen deal

...DRI invested C$3 million (US$2.16 million) in Phytogen, bringing DRI's total investment in the company to...
...bringing DRI's total investment in the company to C$4.5 million. DRI receives increased royalties on Phytogen's...
...the time of an IPO. The deal is part of a C$7 million investment in Phytogen...
BioCentury | Jun 9, 1997
Clinical News

LXR regulatory update

LXR received four U.S. patents and a notice of allowance for a U.S. patent covering its apoptotic compounds. Patent No. 5,567,425 covers methods of preventing apoptosis in cells using plant-derived inhibitors. Patent No. 5,620,888 covers...
BioCentury | Jan 13, 1997
Company News

Draxis, Mylan Laboratories deal

...on a predetermined formula. Mylan manufactures the product using bulk fine chemical paclitaxel produced by Phytogen Life Sciences Inc....
BioCentury | Jul 29, 1996
Company News

Phytogen, Mylan Laboratories Inc. deal

...Phytogen’s Phytogen International LLC subsidiary granted Mylan’s Mylan Pharmaceutical division an exclusive license to sell generic...
...division an exclusive license to sell generic taxol (paclitaxel) in the U.S., Canada and Mexico. Phytogen...
...million (US$1.1 million) to Phytogen in exchange for an undisclosed percentage of revenues from paclitaxel. Phytogen Life Sciences Inc....
BioCentury | Aug 7, 1995
Company News

Drug Royalty Corp., TPL Phytogen Inc., Peptide, Dura deal

...DRI funds are used to finance a sales force expansion. Drug Royalty Corp. (TSE:DRI) TPL Phytogen...
Items per page:
1 - 8 of 8